These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 18583453)
21. Determining the potency and molecular mechanism of action of insurmountable antagonists. Kenakin T; Jenkinson S; Watson C J Pharmacol Exp Ther; 2006 Nov; 319(2):710-23. PubMed ID: 16857731 [TBL] [Abstract][Full Text] [Related]
22. The therapeutic potential of allosteric ligands for free fatty acid sensitive GPCRs. Hudson BD; Ulven T; Milligan G Curr Top Med Chem; 2013; 13(1):14-25. PubMed ID: 23409763 [TBL] [Abstract][Full Text] [Related]
23. The insulin receptor: a prototype for dimeric, allosteric membrane receptors? De Meyts P Trends Biochem Sci; 2008 Aug; 33(8):376-84. PubMed ID: 18640841 [TBL] [Abstract][Full Text] [Related]
24. Changes in the properties of allosteric and orthosteric GABAB receptor ligands after a continuous, desensitizing agonist pretreatment. Gjoni T; Urwyler S Eur J Pharmacol; 2009 Jan; 603(1-3):37-41. PubMed ID: 19109945 [TBL] [Abstract][Full Text] [Related]
25. Analysis of equilibrium binding of an orthosteric tracer and two allosteric modulators. Jakubík J; Randáková A; El-Fakahany EE; Doležal V PLoS One; 2019; 14(3):e0214255. PubMed ID: 30917186 [TBL] [Abstract][Full Text] [Related]
29. The impact of orthosteric radioligand depletion on the quantification of allosteric modulator interactions. Avlani VA; McLoughlin DJ; Sexton PM; Christopoulos A J Pharmacol Exp Ther; 2008 Jun; 325(3):927-34. PubMed ID: 18322151 [TBL] [Abstract][Full Text] [Related]
30. Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. Kenakin T Trends Pharmacol Sci; 2007 Aug; 28(8):407-15. PubMed ID: 17629960 [TBL] [Abstract][Full Text] [Related]
32. A series of 2,4-disubstituted quinolines as a new class of allosteric enhancers of the adenosine A3 receptor. Heitman LH; Göblyös A; Zweemer AM; Bakker R; Mulder-Krieger T; van Veldhoven JP; de Vries H; Brussee J; Ijzerman AP J Med Chem; 2009 Feb; 52(4):926-31. PubMed ID: 19161279 [TBL] [Abstract][Full Text] [Related]
33. Approaches for probing allosteric interactions at 7 transmembrane spanning receptors. Klein MT; Vinson PN; Niswender CM Prog Mol Biol Transl Sci; 2013; 115():1-59. PubMed ID: 23415091 [TBL] [Abstract][Full Text] [Related]
35. Chemical modification of allosteric properties of enzymes. Kemp RG Biol Res; 1996; 29(1):47-56. PubMed ID: 9267516 [TBL] [Abstract][Full Text] [Related]
36. Allostery at opioid receptors: modulation with small molecule ligands. Livingston KE; Traynor JR Br J Pharmacol; 2018 Jul; 175(14):2846-2856. PubMed ID: 28419415 [TBL] [Abstract][Full Text] [Related]
37. Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia. Fraley ME Expert Opin Ther Pat; 2009 Sep; 19(9):1259-75. PubMed ID: 19552508 [TBL] [Abstract][Full Text] [Related]
38. Positive homotropic allosteric binding of benzenediols in a hydrindacene-based exoditopic receptor: cooperativity in amide hydrogen bonding. Kawai H; Katoono R; Nishimura K; Matsuda S; Fujiwara K; Tsuji T; Suzuki T J Am Chem Soc; 2004 Apr; 126(16):5034-5. PubMed ID: 15099063 [TBL] [Abstract][Full Text] [Related]
39. 'Partial' competition of heterobivalent ligand binding may be mistaken for allosteric interactions: a comparison of different target interaction models. Vauquelin G; Hall D; Charlton SJ Br J Pharmacol; 2015 May; 172(9):2300-15. PubMed ID: 25537684 [TBL] [Abstract][Full Text] [Related]
40. Allosteric rescuing of loss-of-function FFAR2 mutations. Swaminath G; Jaeckel P; Guo Q; Cardozo M; Weiszmann J; Lindberg R; Wang Y; Schwandner R; Li Y FEBS Lett; 2010 Oct; 584(19):4208-14. PubMed ID: 20837008 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]